SLC5A2 and obesity disorder: To determine if SGLT2 inhibition promotes improved liver function in the obese TallyHo mice, we challenged both male and females, as well as two control strains—SWR/J (86% genetically identical) and C57BL6J (frequently used in diet-induced obesity studies)—with a high milk-fat diet in the continued presence or absence of Empagliflozin, one of the most well-characterized SGLT2 inhibitors on the market [25].